Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases

Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases

US Patent 10967038 · Granted Apr 6, 2021

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway 2023
Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway 2023
Use for JNK inhibitor molecules for treatment of various diseases2022
Use for JNK inhibitor molecules for treatment of various diseases2022
Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway 2020
Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway 2020
JNK inhibitor molecules for treatment of various diseases2020
JNK inhibitor molecules for treatment of various diseases2020
Protein SLURP-1 for use in the treatment of ocular diseases2018
Protein SLURP-1 for use in the treatment of ocular diseases2018
Protein SLURP-1 for use in the treatment of ocular diseases2018
Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway 2015